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Objectives: This report aimed to evaluate the calculation of estimates of effectiveness in cost effectiveness
analyses of statins for cardiovascular disease prevention.
Methods: Methodological aspects were reviewed of seven primary studies (based on trial results) and 12
secondary modelling studies (extrapolated) on the cost effectiveness of statin treatment, published between
1995 and 2002. Estimates of life years gained were extracted and compared with estimates calculated
using the Dutch male life table of 1996–2000.
Results: Of the seven primary modelling analyses, six showed all the essential data. They estimated that 3
to 5.6 years (average 4.6 years) of statin treatment resulted in 0.15 to 0.41 years (average 0.3 years)
saved over a lifetime time horizon. In contrast none of the 12 secondary modelling studies provided
transparent results. They assumed lifelong treatment, leading to life table estimations of 2.4 and 2.0
(undiscounted) years saved for 40 and 60 year olds, with peak savings at around the mean age of death:
75–80 years. With 5% discounting, these effects reduced to 0.4 and 0.8 years respectively.
Conclusion: Reporting of essential data and assumptions on statin treatment was poor for secondary
modelling analyses and satisfactory for primary modelling studies. Secondary modeling studies made
assumptions on long term effectiveness that were hard to justify with the available evidence, and that led to
the majority of life years saved at high ages. Further standardisation in economic analyses is important to
guarantee transparency and reproducibility of results.
S
tatins reduce the rate of coronary heart disease (CHD)
by over 30%1 with limited side effects.2 However, costs of
statins are substantial. Several costs effectiveness
analyses (CEAs) have been performed to refine indications
for statin use in the prevention of CHD with discrepant
results.3 Cost effectiveness ratios are the ratio of the total
costs of an intervention to the total health effects achieved by
it (for example, years of life saved), when compared with a
null-situation (for example, no intervention).
Years of life saved (YLS) can be derived by comparing the
age specific mortality of treated and control cohorts.4 Given
the mortality risks of the control cohort, the YLS by statin
treatment are defined by the relative risk reduction. A
transparent description of mortality by age in the control
cohort is therefore important, together with either the
relative risk reduction or the mortality by age in the treated
cohort. The different methodologies used to calculate effec-
tiveness estimates may be a source of the divergent results
found among the various CEAs.3 However, the effect and the
level of variation introduced by the different methodological
alternatives in the outcomes remains unclear.
In an attempt to clarify the discrepant results, we reviewed
published CEAs of statins. We aimed to identify the methods
used to quantify the effectiveness of statin treatment and
their influence on the magnitude of the effect estimates
(YLS). We illustrated the different methodologies using a life
table as standard tool.
METHODS
Study selection
We searched for CEAs in English, Spanish, Dutch, or German
on statins for the prevention (primary and/or secondary) of
either CHD or cardiovascular disease. Reviews and meta-
analyses were excluded. Studies needed to compare costs and
effects of statin treatment with no statin treatment and
present discounted or undiscounted cost per YLS as outcome.
Discounting means that years gained later during the life
course are weighted less than years gained nearby. Common
discount rates are 3% and 5%.5 We excluded studies
comparing statins with other statins, or, statins with other
cholesterol lowering drugs.
We used the databases Medline, the British National
Health Service Economic Evaluation Database (NHS EED),
the Database of Abstracts of Reviews of Effectiveness
(DARE), and the Health Technology Assessment database
(HTA). We searched for papers published between 1995 and
June 2004. Before 1995, no evidence from large randomised
trials was available, and the methods of estimating health
effects were diverse.
Two independent investigators analysed the abstracts
obtained from the databases. Studies that matched our
inclusion criteria were retrieved, and their reference lists were
checked to identify other studies. When the decision for
inclusion could not be reached with the abstracts, the papers
were retrieved.
Two investigators read the articles retrieved and selected
the studies based on the inclusion criteria. A third investi-
gator was contacted in case of disagreement.
Data extraction
We focused on the methods used to calculate the effects of
mortality reduction attributable to statin treatment. We
searched for data describing mortality in treated and control
cohorts. We extracted information on the following variables:
time of publication, source of risk for the untreated cohort,
survivorship from the end of treatment, source of risk
reduction for the treated cohort, treatment period ((10
years or .10 years), time horizon (trial duration or lifetime),
and the outcome (YLS).
Abbreviations: CHD, coronary heart disease; YLS, years of life saved;
CEA, cost effective analysis; LE, life expectancy
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Papers were classified by type of modelling: primary or
secondary.6 Primary modelling analyses were defined as
using all data directly collected from randomised controlled
trials (RCTs). In secondary modelling analyses, mortality in
the untreated cohort is either predicted (extrapolated) by risk
functions or taken from other sources such as prospective
cohorts. Mortality reduction was modelled by changes in risk
factor levels (that is, LDL-cholesterol) or by application of
relative risks of mortality or morbidity from published RCTs.
Treatment period and time horizon
The treatment period can be restricted to the trial period
(generally around five years in the case of statins), or can be
assumed to persist after the trial for limited or unlimited
(lifelong) periods. The time horizon is the period of time
considered when calculating the effects of treatment and can
be limited to the trial period or extrapolated for additional
limited or unlimited (lifetime) periods.
The combination of a limited treatment period and a
limited time horizon is presented in figure 1A. Treatment and
treatment effects are restricted to the trial period without
additional extrapolation.
The scenario of combining a limited treatment period
(restricted to the trial) with an unlimited (lifetime) time
horizon is presented in figure 1B: effects seen during the trial
period are extrapolated beyond this time but additional
reductions in mortality risks beyond the period of medication
are not assumed.
An alternative often seen in secondary analyses is to
extrapolate both treatment period and time horizon beyond
the trial period for lifetime: treatment is assumed to continue
until extinction of the cohort or until very old ages (fig 1C).
Life table comparison
We used comparisons with the Dutch male life table of 1996–
2000 to illustrate the effect of different assumptions of
treatment duration and time horizon (fig 1A to 1C) on the
effect estimates (YLS). The Dutch life table was used as a
source of age specific mortality rates in the control cohort.
While this life table does not have identical mortality to any
of the statins trial control arms, its use served as a
standardising tool to translate treatment effects into YLS.
In the Gompertz function of mortality by age, mortality is
predicted by a constant a and a relative increase of mortality
by age of b.7 If we assume b to be constant (and identical to
the Dutch male mortality),8 at any mortality level the
remaining life expectancy (LE) can be determined. The
underlying concept is that of biological more than chron-
ological age, biological age being determined by a certain
observed mortality risk. Higher observed mortality is trans-
lated in shorter life expectancy by the life table. This simple
assumption avoids the many tenuous extrapolations of an
uncertain future, which are a large source of methodological
variability in outcomes of cost effectiveness analyses. LE is
the average number of years that a person of a given age is
expected to remain alive. YLS are the LE of the treated minus
the LE of the control cohort. Effects were calculated using
two scenarios: limited treatment period (five year) and
lifelong treatment period (both with lifetime time horizon).
Results were presented with 0% and 5% discounting. We used
Excel spreadsheets to build the life tables.
RESULTS
Description of the studies
We included 19 studies: 7 primary modelling analyses and 12
secondary (table 1). Data on the mortality rate during the
treatment period were presented for all primary analyses but
only for two of the secondary analyses. Of the primary
analyses,9–15 six presented data on survivorship from the end
of treatment, in contrast with two of the secondary analyses.
All primary analyses considered treatment periods below 10
years, while 11 of the 12 secondary analyses modelled the
effects of lifelong statin treatment.
In primary analyses, YLS had generally two components:
YLS saved during the trial, and YLS expected to be lived
beyond the end of the trial (fig 1B). For example, the
analyses of the 4S trial, which included people with CHD and
hypercholesterolaemia, showed that the treated cohort saved
0.067 life years per person during the trial and 0.312 after it.11
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Figure 1 Assumptions in modelling treatment and time horizons. (A)
Analysis based on treatment and effects seen during the trial period
(treatment effect and time horizon limited to trial period).* (B) The study
extrapolates effects beyond the trial period but does not assume
additional treatment effect (treatment period limited to trial period, time
horizon extrapolated beyond trial period for lifetime). (C) The study
extrapolates beyond the trial period and assumes additional treatment
and effect (that is, same risk reduction as seen during the trial period).
Here both treatment period and time horizon are extrapolated beyond
the trial period.* (*Trial period in the case of statins is generally around
five years, treatment effects of statins taken from LaRossa et al.1)
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This second component was based on the fact that 3.1% more
persons in the treated cohort survived the trial, and were
expected to live on average another 10 years.9 11 16 This leads
to 0.38 YLS/person from 5.15 years of treatment, or 136 years
of treatment to save 10 life years. In six of seven primary
evaluations, all relevant mortality information was presented.
The seventh study described methods but did not present
outcomes for LE after the trial.13
The primary analyses estimated that 3 to 5.6 years (average
4.6) of statin treatment resulted in 0.15 to 0.41 YLS (average
0.3) over a lifetime time horizon.
Of the 12 secondary analyses,17–28 none clearly described the
mortality by age and treatment status.
Life table comparisons
Table 2 mimics the West of Scotland coronary prevention
study (WOSCOPS). This is a large RCT (n = 6595) that
studied the effects of statins among a male population free of
CHD.29 In the treated cohort of WOSCOPS, all cause mortality
was 22% lower than in the control arm.29 This relative risk
reduction was applied to an untreated cohort (from the
Dutch life table) for five years or lifelong.
Table 1 Description of the studies included*
Name and
reference
Publication
year
Untreated cohort Treated cohort Reported data
Source of mortality
Source of risk
reduction
Treatment
duration
(years) Time horizon
Modelling
scheme
(figure 1)
Mortality risks
of control arm
during active
phase of trial
Mortality risk
reduction YLS
Primary analyses
Jo¨nsson9 1996 4S 4S (10 Lifetime B Yes Yes Yes
Johannesson11 1997 4S 4S (10 Lifetime B Yes Yes Yes
Jo¨nsson10 1999 4S 4S (10 Lifetime B Yes Yes Yes
Szucs14 1998 CARE CARE (10 Lifetime B Yes Yes Yes
Szucs15 2000 LIPID LIPID (10 Lifetime B Yes Yes Yes
Ashraf12 1996 PLAC PLAC (10 10 years A Yes Yes Yes
Caro13 1997 WOSCOPS WOSCOPS (10 Lifetime B Yes Yes Yes
Secondary
analyses
Riviere17 1997 4S 4S+survival
functions
.10 Lifetime C No Yes No
Ganz18 2000 Cohort studies CARE .10 Lifetime C No Yes Yes
Huse21 1998 risk function (FHS) risk functions
(FHS)
.10 Lifetime C No No No
Perreault19 1998 risk function (FHS) risk functions
(FHS)
.10 Lifetime C No No Yes
Russel20 2001 risk function (FHS) risk functions
(FHS)
.10 Lifetime C No No No
Hamilton22 1995 risk function (LRC) risk functions
(LRC)
.10 Lifetime C No No Yes
Grover23 1999 risk function (LRC) risk functions
(LRC)
.10 Lifetime C No No Yes
Grover24 2000 risk function (LRC) risk functions
(LRC)
.10 Lifetime C No No Yes
Grover25 2001 risk function (LRC) risk functions
(LRC)
.10 Lifetime C No No Yes
Van Hout26 2001 trials+survival
functions
trials+survival
functions
.10 Lifetime C Yes Yes Yes
Pharoah27 1996 Vital stats+relative
risks
4S/WOSCOPS (10 10 years C Yes Yes No
Pickin28 1999 Vital stats+relative
risks
4S/WOSCOPS.10 Lifetime C No Yes No
YLS, years of life saved; FHS, Framingham heart study; LRC, Lipid Research Clinic cohort. *Studies and available information on health benefits. The duration of life
of untreated cohorts is specified by mortality during treatment and survivorship after treatment. The years of life saved in the treated cohorts are specified by the
mortality reduction, yielding years of life saved. Secondary analyses have rarely sufficient information to judge the validity of the results.
Table 2 Effects of allocation to statin treatment on male mortality risks using the results of the WOSCOPS* trial for the effects of
statin treatment and mortality risks in Dutch men (1996–2000) for mortality risks in the absence of statin treatment: life table
simulation
Exact age
Untreated Treated
Treatment period
Lifelong Five years
Five year risk of
death LE LE disc 5%
Risk
reduction` YLS YLS disc 5% YLS five year
YLS five year disc
5%
40 0.9% 36 17 0.2% 2.4 0.4 0.07 0.03
50 2.5% 27 15 0.5% 2.3 0.6 0.12 0.06
60 7.2% 18 12 1.5% 2.0 0.8 0.27 0.15
70 20% 11 8.3 4.0% 1.7 0.9 0.45 0.30
80 46% 6.3 5.2 8.3% 1.2 0.8 0.60 0.46
LE, life expectancy; YLS, years of life saved; disc, discounted. *WOSCOPS trial (five year risk of death 4,17% at age 55, 22% reduction in all cause mortality)
extrapolated to younger and older ages. The same risk reduction is translated in four life table measures by two treatment periods: until the end of life (lifelong) and
over five years both over a lifetime time horizon. 5% means that an annual discount rate of 5% is applied to the saved life years in the future cohort. The YLS apply
to the survivors at age x. Risk of dying between age x and x+5. `Risk reduction in the treated cohort, the risk is 22% lower (WOSCOPS trial).
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The YLS were higher the younger the treatment started
(table 2). When we assumed that treatment started at age 40
and continued lifelong, a 22% reduction in all cause mortality
saved 2.4 years. Most life years were however saved around
the mean age of death in this population (76 years). After
discounting by 5%, only 0.42 life years were saved (5.7 times
less than the undiscounted values).
When only the savings of treating between age 40 and 45
were considered, combined with a lifetime time horizon (for
example, fig 1B), a 22% reduction in all cause mortality saved
0.07 years.
In other words, 71 years of treatment would save one life
year. An example of the effect obtained by treating a cohort
aged 40–45 over a five year treatment period with benefits
accumulated over a lifetime is shown in figure 2. An
alternative would be to calculate this effect over a lifelong
treatment period combined with a lifetime time horizon
(fig 3).
Life table comparisons with primary modelling
Using the above method we compared the YLS estimates
from each study with estimates derived from the Dutch life
tables.
The estimate (YLS) of the 4S evaluators (0.38) was close to
our life table estimate (0.41) (table 3), consistent with a
slightly lower estimate of the YLS of survivors at the end of
the trial compared with our estimate. The LIPID trial’s
estimate was higher than ours (0.41 compared with 0.34
years), consistent with a LE at the end of trial that was 2.7
years higher than that of our life table (table 3). For the
CARE trial, YLS were 0.22 compared with 0.15 years, again
consistent with a lower LE of our life table. For the
WOSCOPS trial, the estimated 0.25 YLS by treatment was
higher than our estimate of 0.10 YLS. The WOSCOPS’ authors
included estimates of an improved prognosis for the survivors
without a CHD event, and this could explain the difference.
Finally, Ashraf et al12 presented all relevant data, but analysed
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Figure 2 Predicted effects per person allocated to statin treatment between exact age 40 to 45 using a five years limited treatment effect with a lifetime
time horizon assumption: distribution of life years saved by the ages at which they are lived. (Savings in each five year age group by a fixed reduction
of mortality risks between exact age 40 and exact age 45. The life years saved after exact age 45 are those lived during each age interval by the
additional survivors to exact age 45.)
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Figure 3 Predicted effects per person of a 40 year old cohort allocated to statin treatment using a lifelong treatment effect with lifetime time horizon
assumption: distribution of life years saved by the ages at which they lived. (Savings in each five year age group by a fixed reduction of mortality risk,
of a 40 year old cohort over the future, assuming lifetime effect and treatment. Note that most savings will fall more than three decades after start of
treatment.)
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only 10 CHD deaths and six of other causes (data from the
PLAC trial, not presented in table 3).
From the 12 secondary modelling analyses included, none
clearly presented the modelled age specific mortality rates of
treated and untreated cohorts. Therefore, we could not
compare them with the life table estimates to illustrate their
methodologies.
DISCUSSION
Within the scientific literature, the benefits of statin
treatment in primary and secondary modelling analyses have
been calculated with quite different assumptions about
treatment period and treatment effect. Primary modelling
analyses used mostly a treatment period equal to trial period
and a lifetime time horizon while secondary modelling
analyses assumed a lifelong treatment period and time
horizon. Most primary modelling analyses considered the
direct YLS during the trial, and combined these with YLS
after the trial by the extra survivors who shared the LE of the
control cohort (fig 1B). All secondary analyses extrapolated
the treatment’s effects to periods of time far beyond the
available evidence.
Overall we were confronted with a poor transparency in
the presentation of essential data among secondary model-
ling cost effectiveness analyses of statins. This constituted an
important impediment to the interpretation and evaluation
of the selected studies.
Of the 19 evaluated studies, only six showed all the
information on their age specific mortality rates. All six were
primary analyses. A seventh primary analysis, the WOSCOPS
study evaluation, was thorough but failed to show how
prevented CHD affected survivorship after the trial period.
This implied that a large part of the savings remained
Table 3 Trial characteristics, and years of life saved by treatment*: life table simulation
and comparison using data on mortality risks taken from the Dutch male population
Trials
4S LIPID CARE WOSCOPS
AFCAPS/
TexCAPS
N 4444 9014 4159 6595 6605
Follow up (mean y) 5.4 6.1 5.0 4.9 5.2
Age (mean, y) 59 62 59 55 58
Men (%) 81 83 86 100 85
History of MI (%) 79 64 100 0 0
TC/HDL ratio 5.67 6.06 5.35 6.17 6.01
Control arm
Five year risk of death (%) 10.7 11.7 9.4 4.2 2.2
Five year risk of CHD death (%) 7.90 6.84 5.73 1.61 0.44
Lived during trial (y) 4.77 4.74 4.97 4.90 4.95
Life expectancy (LE, y) 15.7 15.1 16.7 22.6 28.1
LE at end of trial (y) 10.93 10.36 11.73 17.70 23.15
Statin arm
Absolute risk reduction of all
cause mortality (%)
3.10 2.54 0.78 0.91 20.09
Years saved during trial 0.067 0.074 0.023 0.024 0.003
Based on all cause mortality
Total years saved` 0.41 0.34 0.11 0.18 Harm
Based on CHD mortality
Total years saved` 0.42 0.24 0.15 0.10 0.03
Published estimates
0.389 0.4115 0.2214 0.2513
0.3510
*The savings are calculated by two methods: using absolute reduction in all cause or in coronary heart disease
mortality. Years lived are based on the life table of Dutch men 1996–2000 (see text). At a five year risk of death of
10.7% (4S trial), Dutch men had a residual life expectancy of 15.7 years. `Years lived during the trial plus the
absolute mortality reduction multiplied by the residual life expectancy at the end of the trial.
What is already known on the topic
N Statins reduce the rate of coronary heart disease by
over 30% with limited side effects, but statins’ costs are
substantial.
N Several cost effectiveness analyses have been per-
formed to refine indications for statin use in the
prevention of coronary heart disease with discrepant
results.
N One potential source of the divergent results found in
the various cost effectiveness analyses has been
suggested to be the different methodologies used to
calculate the effectiveness estimates. However, the
effect and the level of variation introduced by the
different methodological alternatives in the outcomes
remains unclear.
What this paper adds
N Reporting of essential data was poor for secondary
modelling cost effectiveness analyses and satisfactory
for primary modelling cost effectiveness analyses on
statins.
N Cost effectiveness analyses that used secondary
modelling made assumptions on long term effective-
ness that were hard to justify with the available
evidence, and that led to the majority of life years
saved at high ages.
N Primary modelling analyses had close links with
underlying data from randomised controlled trials,
reported better and made more reasonable assump-
tions; hence they should be viewed with more
confidence than cost effectiveness analyses that use
secondary modelling.
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without a clear explanation. Of the six primary analyses that
showed sufficient information, one study described a small
population: resulting in very wide confidence limits.12 That
left five studies for serious evaluation, which described the
experience of the 4S, LIPID, and CARE trials. Among these,
the 4S publications showed all the essential information most
clearly. Additionally the results were consistent with our life
table approach. Depending on the data and method used for
estimating survival at the end of the trial, 11 to 13 years of
statin treatment added one year of life.
From the 12 secondary modelling analyses included, none
clearly presented the modelled age specific mortality rates of
treated and untreated cohorts, leaving the reader with
aggregate outcomes that could not be fully interpreted or
reproduced. As health benefits are the primary aim of any
health intervention, in future publications the modelled age
specific event rates of the control and intervention cohort
should be clearly shown. Most of the secondary analyses used
lifelong treatment periods. Modelling treatment over lifelong
periods requires assumptions on treatment effects over
unobserved long periods and at old ages. The argument that
considering lifelong treatment effect is ‘‘a more realistic
assumption, as treatment is for life’’28 calculates health
benefits at an old age (.70 years) with limited evidence and
at a time the studied drugs might be superseded by cheaper
substitutes, or a polypill.30 To model the effect of a drug, it is
not necessary to stretch the evidence far beyond observable
time periods. As far as evidence is available, statins decrease
the risk of CHD regardless of the duration they are taken
(after a short lag time period).26 Risk reduction is around
30%,1 regardless if statins have been taken for two or five
years. There is therefore no need to assume a lifelong
treatment effect.
For our life tables, we used only data from Dutch men. We
do not think this affects our conclusions as we used these
data only to illustrate the different alternatives in methodol-
ogies and to increase comparability within the analysed
studies.
It is also possible that some relevant studies were not
included in this analysis, but we do not think this would
change our conclusions. We excluded three cost-utility
analyses31–33 that did not present YLS, as our objective was
to analyse the calculation methods of effectiveness and not of
utilities. The outcome for cost-utility studies is years of life
gained adjusted by quality weights (QALYs). YLS are solely
derived from age specific mortality in treated and untreated
cohorts. QALYs require estimates of incidence of disease
stages, duration of these stages, and value judgments on the
utility lost by decreased health in these stages. This limits the
comparability.
In the particular scenario of statins for cardiovascular
disease prevention, competing interests are important.34 This
increases the necessity for robust methodology and trans-
parent reporting. The advent of the internet lessens the space
restrictions in paper journals. This may allow for the
provision of detailed information in the world wide web,
aiding the transparency in the reporting.
We found that reporting of essential data was poor for
secondary modelling analyses and satisfactory for primary
analyses on statins. Primary modelling analyses had close
links with underlying data from randomised controlled trials,
reported better and made more reasonable assumptions;
hence they should be viewed with more confidence than
secondary modelling studies. Better cost effectiveness ana-
lyses are rooted in the evidence of trials. The value of added
survivorship in treated cohorts should be translated into YLS
by transparent and interpretable methods (as seen in primary
modelling analyses). Further standardisation in economical
analyses is important to guarantee transparency and repro-
ducibility of results.
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